Aileron Therapeutics, Inc. ALRN
Set alert
At close · Jan 10
52-week range unavailable
- Open
- 1.97
- Prev close
- 2.11
- Mkt cap
- 47.02M
- Vol
- 63.39K
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.96
- High
- 2.17
- Forward P/E
- -1.22
- Beta
- 2.34
- Short ratio
- 3.47
- Inst. own
- 28.47%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 3.03
- 200-d avg
- 3.47
- 1y target
- 13.00
Key statistics
- Market cap
- 47.02M
- Enterprise value
- 85.27M
- Trailing P/E
- 0.00
- Forward P/E
- -1.22
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 1.54
- EPS (TTM)
- -2.88
- Beta
- 2.34
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -12.07M
- Total cash
- 21.92M
- Total debt
- 0
- Return on equity
- -44.32%
- Shares outstanding
- 21.67M
- Short % of float
- 1.08%
- 50-day average
- 3.03
- 200-day average
- 3.47
Analyst view
Consensus: none
- Target (low)
- 7.00
- Target (mean)
- 13.00
- Target (high)
- 19.00
- Strong buy0
- Buy2
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.48.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | -0.25 | -0.27 | -0.02 | -8.00% |
| Aug 14, 2024 | Jun 1, 2024 | -0.25 | -0.45 | -0.20 | -80.00% |
| May 15, 2024 | Mar 1, 2024 | 0.00 | -0.86 | — | — |
| Apr 15, 2024 | Dec 1, 2023 | 0.00 | -1.54 | — | — |
| Oct 13, 2023 | Sep 1, 2023 | 0.00 | -0.40 | — | — |
| Aug 11, 2023 | Jun 1, 2023 | 0.00 | -0.39 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Apr 18, 2024 | Ladenburg Thalmann | main | Buy | Buy |
| Dec 1, 2023 | Ladenburg Thalmann | up | Neutral | Buy |
About Aileron Therapeutics, Inc.
Aileron Therapeutics, Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). Its second product candidate is LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion. The company's pipeline also includes preclinical programs targeting cystic fibrosis and a peptide program focused on the caveolin-1 protein for systemic fibrosis indications. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is headquartered in Austin, Texas.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- aileronrx.com
News
- Aileron Therapeutics Announces Rebranding to Rein Therapeutics
- Aileron Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
- Aileron Therapeutics Announces Positive Topline Data from Cohort 2 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)
- Aileron Therapeutics and Advancium Health Network Announce an Exclusive Option Agreement for the Acquisition of ALRN-6924 for Retinoblastoma
- Aileron Therapeutics to Present Previously Announced Data from the Phase 1b Clinical Trial Evaluating Low-Dose LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) at the 22nd International Colloquium on Lung and Airway Fibrosis
- Aileron Therapeutics Completes Enrollment in Cohort 2 of the Ongoing Phase 1b Clinical Trial Evaluating LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)
- Aileron Therapeutics to Present at the 8th Annual IPF Summit
- Aileron Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights
- Aileron Therapeutics to Present at the Canaccord Genuity 44th Annual Growth Conference
- Aileron Therapeutics to be Included in the Russell Microcap® Index
Your note
Sign in to keep a note on ALRN — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| UNIVERSITY OF TEXAS INVESTMENT MANAGEMENT | Beneficial Owner of more than 10% of a Class of Security | Sale | Jun 16, 2024 | 1,746,550 |
| WINDSOR JAMES BRIAN | Chief Executive Officer | Purchase | Dec 4, 2024 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| University of Texas/Texas AM Investment Managment Co | 6.48% | 1,403,339 | 3.05M | Sep 29, 2024 |
| Alyeska Investment Group, L.p. | 2.49% | 540,000 | 1.17M | Sep 29, 2024 |
| Nantahala Capital Management, LLC | 2.14% | 464,367 | 1.01M | Sep 29, 2024 |
| Vanguard Group Inc | 1.99% | 432,201 | 937.88K | Sep 29, 2024 |
| Cable Car Capital LLC | 1.94% | 420,000 | 911.40K | Sep 29, 2024 |
| Prosight Management, Lp | 1.72% | 372,157 | 807.58K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 1.94% | 419,427 | 910.16K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.51% | 111,248 | 241.41K | Oct 30, 2024 |
| iShares Micro Cap ETF | 0.21% | 45,857 | 99.51K | Oct 30, 2024 |
| Fidelity NASDAQ Composite Index ETF | 0.19% | 40,699 | 88.32K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.16% | 35,681 | 77.43K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.12% | 25,112 | 54.49K | Oct 30, 2024 |